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Abstract
Background: Tigecycline is a novel antibiotic with activity against multidrug resistant bacteria. The aim of this
study was to assess the efficacy of tigecycline use in serious hospital-acquired infections (HAI)
Case presentation: Prospective observational study of tigecycline use was conducted in a 1500 beds university
hospital. From January 1, 2007 and January 31, 2010, 207 pts were treated with tigecycline for the following
indications: intra-abdominal, pneumonia, bloodstream and complicated skin and soft tissue infections and febrile
neutropenia. The therapy was targeted in 130/207 (63%) and empirical in 77/207 (37%) patients. All bacteria treated
were susceptible to tigecycline. Median duration of tigecycline therapy was 13 days (range, 6-28). Clinical success
was obtained in 151/207 (73%) cases, with the highest success rate recorded in intra-abdominal infections [81/99
(82%)]. Microbiological success was achieved in 100/129 (78%) treated patients. Adverse clinical events were seen
in 16/207 patients (7.7%):
Conclusions: Considering the lack of data on tigecycline for critically ill patients, we think that the reported data
of our clinical experience despite some limitations can be useful for clinicians.
Background
The management of hospital-acquired bacterial infec-
tions is becoming a significant challenge for health care
providers because of the increased prevalence of multi-
drug-resistant (MDR) bacteria like methicillin-resistant
Staphylococcus aureus (MRSA), vancomycin-resistant
Enterococcus spp. (VRE), Acinetobacter baumannii, Kleb-
siella pneumoniae, carbapenemase -producing Entero-
bacteriaceae, and extended-spectrum beta-lactamase
(ESBL)-producing Enterobacteriaceae. Increased mor-
bidity and mortality, duration of hospitalization, and
medical care costs are all associated with MDR organ-
isms [1]. Delay of appropriate empiric antimicrobial
therapy is known to increase morbidity and mortality
among affected patients and inadequate therapy has
been found to be associated with excess mortality and
increased duration of hospitalization [2]. There is a high
rate of resistance to commonly used antimicrobial
agents, including beta-lactams (penicillins and cep-
halosporins), fluoroquinolones, aminoglycosides and
glycopeptides, which may reduce the effectiveness of
these drugs.
Tigecycline is a new glycylcycline antibitiotic that has
come into clinical use at a critical time and demon-
strates in vitro activity against a wide range of bacteria
[3,4]. Tigecycline has been approved by the Food and
Drug Administration (FDA) and the European Medi-
cines Agency (EMEA) for the treatment of complicated
intra-abdominal and skin and soft tissue infections [5,6].
Besides, FDA recently approved it for the treatment of
community-acquired pneumonia [7]. However, the role
of tigecycline in the treatment of infections due to MDR
bacteria remains undefined.
We conducted a prospective study to determine both
clinical and microbiological outcomes of patients treated
with tigecycline for serious hospital-acquired infections
(HAI).
Methods
The study was conducted at the San Martino Hospital, a
1500-bed, academic, tertiary care medical centre in
Genoa (Italy). All adult subjects admitted to the hospital
who received ≥48 h of treatment with tigecycline
between January 1, 2007 and January 31, 2010 for
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standard FDA and EMEA -approved dosage of tigecy-
cline (initial loading dose of 100 mg, followed by 50 mg
administered intravenously every 12 h). Identification
and susceptibility testing of bacterial isolates were
performed by standard techniques, with the use of a
semi-automated system (Vitek 2; bioMerieux). Clinical
data was collected from medical records and included
age, sex, comorbidities, APACHE II score, clinical diag-
nosis, microbiologic isolate identification with antibiotic
susceptibility, concomitant antibiotics, indication for
tigecycline use, duration of tigecycline treatment and
adverse clinical events.
Established criteria were used to define an hospital-
acquired infection [8]. Secondary peritonitis was defined
as a result of spillage of gut organisms through a physi-
cal hole in the gastrointestinal tract or through a necro-
tic gut wall and included intra-abdominal abscess
(including liver, spleen and pancreatic), perforated diver-
ticulitis complicated by abscess formation or fecal con-
tamination; complicated cholecystitis with evidence of
perforation, empyema, or gangrene; perforation of a gas-
tric or duodenal ulcer; purulent peritonitis or peritonitis
associated with fecal contamination; or perforation of
the large or small intestine with abscess or fecal con-
tamination; tertiary peritonitis was defined a peritonitis
in a critically ill patient which persists or recurs at least
48 h after apparently adequate management of primary
or secondary peritonitis. Empirical use of tigecycline was
defined as the administration of treatment to a patient
with signs and symptoms of infection without an identi-
fied source or a specific microbiological isolate. Targeted
therapy was defined as the antibiotic administration in
presence of an identified isolate.
Clinical response at the end of treatment was defined as
positive response (partial or complete improvement of
signs/symptoms of infection), negative response (no
improvement or deterioration of signs/symptoms of infec-
tion), or uncertain response. Microbiological response was
defined as positive response (sterile culture results during
or after the course of antibiotic therapy), negative response
(persistent identification of the same organism for 3 days
after initiation of antibiotic treatment), or not documented
response. The overall response was considered positive if
any of the positive criteria of microbiological response
were met.
The study was approved by the local institutional review
board (Comitato Etico, Azienda Ospedaliera Universitaria
San Martino, Genova, Italy) and patient consent was not
required because of the observational nature of this study.
Cases presentation
Two hundred and seven patients received tigecycline ther-
apy for ≥48 h within our facility during the defined study
period for the treatment of HAI. The clinical characteris-
tics of the patients were reported in Table 1. Tigecycline
was mainly used in the following wards: general surgery,
oncology, haematology and intensive care. The therapy
was targeted in 130/207 (63%) and empirical in 77/207
(37%) patients. All bacteria treated were susceptible
to tigecycline. Median duration of tigecycline therapy was
13 days (range, 6-28) (table2). In table 2 type of infections
and clinical efficacy of tigecycline are detailed. Table 3
details bacterial isolates and eradication rates. In 161/207
(78%) cases tigecycline was used as monotherapy, while
46/207 (22%) patients received tigecycline as part of a
combination therapy, mainly associated with colistin (19/
46; 41%), meropenem (11/46; 24%), amikacin (9/46; 20%),
or ciprofloxacin (7/46; 15%). Clinical success was obtained
in 151/207 (73%) cases, with the highest success rate
recorded in intra-abdominal infections [81/99 (82%)].
Microbiological success was achieved in 100/129 (78%)
treated patients. Adverse clinical events were seen in 16/
207 patients (7.7%): 5 (2.4%) experienced mild nausea, and
12 (5.8%) experienced nausea and vomiting, while 7 (3.4%)
experienced an increasing in liver enzymes. Only 4 (1.9%)
of the total 207 patients experienced diarrhoea on tigecy-
cline, all of whom were negative for C. difficile toxin in
stools. Only one patient interrupted tigecycline in reason
of adverse effects (profuse vomiting and nausea).
Conclusions
We described 207 patients who received tigecycline
under real-life conditions of daily clinical practice for
empiric or targeted treatment of serious HAI. Tigecy-
cline was used to treat a variety of infections, including
many that were not indicated in official FDA and EMEA
labelling for tigecycline. Despite the fact that most of
Table 1 Clinical characteristics of patients at start of
tigecycline
n, 207
Gender, n (%)
Male 118 (57)
Age, yrs
Median 63
Range 14-89
Apache II score
Mean (± SD) 21 ± 8.8
Range 8-45 8-45
Admitted to ICU, n (%) 83 (40)
Co-morbid conditions, n (%)
Solid tumor 79 (38)
Hematologic malignancy 50 (24)
Diabetes mellitus 48 (23)
Neutropenia (< 500 mm3) 29 (14)
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they had high APACHE II scores at the time of tigecy-
cline administration, the overall clinical outcomes were
good. The patients analyzed in this prospective study
constitute the biggest relevant cohort. Successful clinical
response rates of 82% were recorded for intra-abdominal
infections and 78% for complicated skin and soft tissue
infections with an overall successful clinical response of
73%. The mean clinical response rate was lower in
patients with febrile neutropenia, pneumonia and bac-
teremia (58%, 67% and 70%, respectively). The popula-
tion represented in this study included a significantly
higher proportion of seriously ill patients which was not
captured in the Phase 3 registration trials for each thera-
peutic indication. In a pooled analysis of two Phase 3
double-blind trials of tigecycline versus imipenem-cilastatin
in patients with complicated intra-abdominal infection,
the mean APACHE II score of tigecycline-treated patients
was 6.3, and only 3.5% of them had an APACHE II score
higher than 15; an APACHE II score of more than 20 was
an exclusion criterion in those studies [5]. The population
treated in our study mirrors the typical patients with
complicated HAI and significantly higher APACHE II
scores (mean score of 21) and thus higher disease severity
and the data confirm similar recent experiences [9,10].
In addition, the majority of the patient population
experienced co-morbidities leading to a higher risk of
infections with MDR bacteria.
In approximately half of the patients, complicated
intra-abdominal infections were involved, including
MRSA and Enterococcus spp infections. We observed a
remarkably high proportion of enterococcal infections
and among them tigecycline had a success rate of 76%,
similar to the microbiological efficacy obtained against
MRSA (80%). Regarding the anti-Gram-negative efficacy,
tigecycline confirms its effectiveness especially for E. coli
(81%) and A. baumannii ( 69%). This data confirms
recent similar experiences reported [11-14]. The majority
of patients received tigecycline in monotherapy and only
22% of patients were treated with tigecycline in combina-
tion with other broad-spectrum antibiotics to expand the
range of activity against P. aeruginosa.
In this non-comparative trial, tigecycline appeared safe
and effective in the treatment of serious HAI caused by
resistant bacteria. The data from this study is consistent
with larger pivotal studies of tigecycline treatment of
serious infections [5-7]. For these reasons, tigecycline
may be useful as an addition to the clinician’s antimicro-
bial therapy options for difficult-to-treat resistant patho-
gens associated with serious nosocomial infections and
also as part of an overall infection control and pharmacy
intervention as suggested in the current guidelines [15].
Table 2 Type of infections, duration of treatment and clinical efficacy of tigecycline
Type of infections n (%) Duration of treatment, days
Median (range)
Clinical efficacy
n (%)
Clinical failure
n (%)
Secondary peritonitis 46 (22) 9 (6- 18) 40 (88) 6 (12)
Tertiary peritonitis 41 (20) 15 (11-28) 32 (78) 9 (22)
Other abdominal infections 12 (6) 11 (7-17) 5 (42) 7 (58)
Pneumonia ( HAP, HCAP, VAP) 27 (13) 12 ( 8-21) 18 (67) 9 (33)
Pneumonia and bloodstream infections 29 (14) 17 (13-24) 19 (66) 10 (34)
Bloodstream infections 23 (11) 15 (12-18) 16 (70) 7 (30)
Complicated skin and soft tissue infections 17 (8) 11 (7-18) 13 (76) 4 (24)
Empiric use in neutropenic 12 (6) 14 (9-17) 7 (58) 5 (42)
Total 207 (100) 151 (73) 56 (27)
HAP: hospital acquired pneumonia, HCAP: health care associated pneumonia, VAP: ventilator associated pneumonia.
Table 3 Bacterial isolates treated with tigecycline and eradication rate
Bacterial isolates n (%) Microbiological efficacy
n (%)
Microbiological failure
n(%)
Enterococcus faecium 31 (24) 22/31 (71) 9/31 (29)
Escherichia coli 26 (20) 21/26 (81) 5/26 (19)
Methicillin-resistant Staphylococcus aureus 20 (15) 16/20 (80) 4/20 (20)
Acinetobacter baumannii 16 (12) 11/16 (69) 5/16 (31)
Klebsiella pneumoniae 15 (12) 13/15 (89) 2/15 (11)
Enterobacter cloacae 10 (8) 8/10 (80) 2/10 (20)
Enterococcus faecalis 6 (5) 6/6 (100) 0/6
Others 5 (4) 3/5 (60) 2/5 (40)
Total 129 100/129 (78) 29/129 (22)
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Page 3 of 4The results should be viewed as purely descriptive, as
this was an observational, prospective analysis of data
from 207 patients who had received tigecycline in our
hospital and no control group of patients (treated with
drugs other than tigecycline) was analysed in this assess-
ment. Considering the lack of data on newly approved
antimicrobial agents for critically ill patients, we think
that the reported data of our clinical experience with
tigecycline, despite the limitations discussed can be use-
ful for clinicians.
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